Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective

Annals of Hematology

Volumn 89, Issue 12, 2010, Pages 1239-1247

  Kühne, Felicitas ^a   Mittendorf, Thomas ^a   Germing, Ulrich ^b   Tesch, Hans ^c   Weinberg, Reiner ^d   Grabenhorst, Ulrich ^e   Mohr, Andreas ^f   Lipp, Rainer ^g   Von Der Schulenburg, Johann Matthias ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Private Practice   (Germany)

^d Private Practice   (Germany)

^e Private based Oncology Practice   (Germany)

^f Private Practice   (Germany)

^g Innovation Oncology Research and Consulting (IORC) GmbH   (Germany)

Author keywords

Cost analyses; Cost of illness; Economic analysis; Myelodysplastic syndromes

Indexed keywords

ERYTHROPOIETIN; IRON CHELATING AGENT;

AGED; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME DELETION 5; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTPATIENT CARE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 78549238147     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1017-y     Document Type: Article

References (36)

1. U Germing C Strupp A Kundgen D Bowen C Aul R Haas, et al. 2004 No increase in age-specific incidence of myelodysplastic syndromes Haematologica 89 905 910 15339672
2. X Ma M Does A Raza ST Mayne 2007 Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 1536 1542 10.1002/cncr.22570 17345612 (Pubitemid 46595689)
3. U Germing C Strupp A Kuendgen S Isa S Knipp B Hildebrandt, et al. 2006 Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes Haematologica 91 1596 1604 17145595
4. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman, et al. 2000 The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997 Hematol J 1 53 66 1:STN:280:DC%2BD387oslCltg%3D%3D 10.1038/sj.thj.6200013 11920170
5. Brunning RD, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon
6. D Haase U Germing J Schanz M Pfeilstocker T Nosslinger B Hildebrandt, et al. 2007 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 4385 4395 1:CAS:528:DC%2BD1cXot1Sq 10.1182/blood-2007-03-082404 17726160 (Pubitemid 351377805)
7. S Heim F Mitelman 1986 Chromosome abnormalities in the myelodysplastic syndromes Clin Haematol 15 1003 1021 1:STN:280:DyaL2s7ovVCktQ%3D%3D 3552345
8. F Sole B Espinet GF Sanz J Cervera MJ Calasanz E Luno, et al. 2000 Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica Br J Haematol 108 346 356 1:CAS:528:DC%2BD3cXitFCgsLg%3D 10.1046/j.1365-2141.2000.01868.x 10691865 (Pubitemid 30143651)
9. J Boultwood S Lewis JS Wainscoat 1994 The 5q-syndrome Blood 84 3253 3260 1:CAS:528:DyaK2cXmvFyjt7Y%3D 7949083
10. AA Giagounidis U Germing S Haase B Hildebrandt B Schlegelberger C Schoch, et al. 2004 Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 Leukemia 18 113 119 1:STN:280:DC%2BD3srpslCrtw%3D%3D 10.1038/sj.leu.2403189 14586479 (Pubitemid 38159446)
11. T Goss A Szende C Schaefer R Knight K Heptinstall M Lübbert, et al. 2007 Value of transfusion free living in MDS: results of health utility reviews with patients Leuk Res 31 S105 S106 10.1016/S0145-2126(07)70192-3
12. L Malcovati M Della Porta C Pascutto R Invernizzi F Passamonti L Arcaini, et al. 2005 The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome Blood (ASH. Annual Meeting Abstracts) 106 791
13. L Malcovati MG Porta C Pascutto R Invernizzi M Boni E Travaglino, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
14. JR Frytag H Henk M Nelson C DeCastro 2005 Economic burden of transfusion dependence in patients with myelodysplastic syndromes Proc Annu Meet Am Soc Clin Oncol 23 6064
15. P Gupta SC LeRoy SD Luikart A Bateman VA Morrison 1999 Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications Leuk Res 23 953 959 1:STN:280: DC%2BD3c%2FjslyisQ%3D%3D 10.1016/S0145-2126(99)00113-7 10573142 (Pubitemid 29460832)
16. N Gattermann 2007 Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload Leuk Res 31 Suppl 3 S10 S15 1:CAS:528:DC%2BD2sXhtlGhsrrE 10.1016/S0145-2126(07)70461-7 18037413 (Pubitemid 350137502)
17. PD Jensen L Heickendorff B Pedersen K dix-Hansen FT Jensen T Christensen, et al. 1996 The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br J Haematol 94 288 299 1:STN:280: DyaK28zis1agsw%3D%3D 10.1046/j.1365-2141.1996.d01-1795.x 8759889
18. RD Propper B Cooper RR Rufo AW Nienhuis WF Andersen HF Bunn, et al. 1977 Continuous subcutaneous administration of deferox-amine in patients with iron overload N Engl J Med 297 418 423 1:STN:280:DyaE2s3jt1Kiug%3D%3D 10.1056/NEJM197708252970804 882111
19. S Park S Grabar C Kelaidi O Beyne-Rauzy F Picard V Bardet, et al. 2008 Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood 111 574 582 1:CAS:528:DC%2BD1cXns1CgtQ%3D%3D 10.1182/blood-2007-06-096370 17940203
20. KB Miller HT Kim P Greenberg R van der Jagt JM Bennett MS Tallman, et al. 2004 Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG trial (E1996) Blood (ASH. Annual Meeting Abstracts) 104 70
21. M Jadersten SM Montgomery I Dybedal A Porwit-MacDonald E Hellstrom-Lindberg 2005 Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF Blood 106 803 811 10.1182/blood-2004-10-3872 15840690 (Pubitemid 41076418)
22. JA Thompson DG Gilliland JT Prchal JM Bennett K Larholt RA Nelson, et al. 2000 Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome Blood 95 1175 1179 1:CAS:528:DC%2BD3cXhtFKisbo%3D 10666187
23. E Hellstrom-Lindberg N Gulbrandsen G Lindberg T Ahlgren IM Dahl I Dybedal, et al. 2003 A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 1037 1046 1:CAS:528:DC%2BD3sXjsVaksbw%3D 10.1046/j.1365-2141.2003.04153.x 12648074 (Pubitemid 36411563)
24. E Hellstrom-Lindberg T Ahlgren Y Beguin M Carlsson J Carneskog MD Dahl, et al. 1998 Treatment of anemia in myelodysplastic syn-dromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients Blood 92 68 75 1:CAS:528:DyaK1cXktlerur0%3D 9639501
25. L Mannone C Gardin MC Quarre JF Bernard D Vassilieff L Ades, et al. 2006 High-dose darbepoetin alpha in the treatment of anemia in lower risk myelodysplastic syndrome: results of a phase II study Br J Haematol 133 513 519 1:CAS:528:DC%2BD28Xmt1yisrY%3D 10.1111/j.1365-2141.2006.06070.x 16681638
26. M Dimopoulos A Spencer M Attal M Prince JL Harousseau A Dmoszynska, et al. 2007 Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma N Engl J Med 357 2123 2132 1:CAS:528:DC%2BD2sXhtlGis7nN 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
27. A List AF Baker S Green W Bellamy 2006 Lenalidomide: targeted anemia therapy for myelodysplastic syndrome Cancer Control 13 4 11 17242661 (Pubitemid 46148104)
28. A List G Dewald J Bennett A Giagounidis A Raza E Feldman, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456 1465 1:CAS:528:DC%2BD28XhtVGgtrvO 10.1056/NEJMoa061292 17021321 (Pubitemid 44511560)
29. DM Weber C Chen R Niesvizky M Wang A Belch EA Stadtmauer, et al. 2007 Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America N Engl J Med 357 2133 2142 1:CAS:528:DC%2BD2sXhtlGis7bM 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
30. P Fenaux GJ Mufti V Santini C Finelli A Giagounidis R Schoch, et al. 2007 Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study Blood (ASH. Annual Meeting Abstracts) 110 817
31. P Fenaux GJ Mufti E Hellstrom-Lindberg V Santini C Finelli A Giagounidis, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223 232 1:CAS:528:DC%2BD1MXisFWjsbc%3D 10.1016/S1470-2045(09)70003-8 19230772
32. S Brechignac E Hellstrom-Lindberg D Bowen T DeWitte M Cazzola P Fenaux 2004 Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS) Blood 104 263b 10.1182/blood-2003-08-2841 (Pubitemid 38879867)
33. N Casadevall P Durieux S Dubois F Hemery E Lepage MC Quarre, et al. 2004 Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial Blood 104 321 327 1:CAS:528:DC%2BD2cXlvFSnsbg%3D 10.1182/blood-2003-07-2252 15054036 (Pubitemid 38900010)
34. JR Frytag H Henk CM De Castro R Halpern 2007 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes Leuk Res 31 S111 S112 10.1016/S0145-2126(07)70202-3
35. T Goss A Szende C Schaefer PJ Totten R Knight M Jädersten, et al. 2006 Cost effectiveness of lenalidomide in the treatment of transfusion- dependent myelodysplastic syndromes in the United States Cancer Control 13 17 25 17242663
36. TA Hodgson 1988 Annual costs of illness versus lifetime costs of illness and implications of structual change Drug Inf J 22 323 341